Inflammation, coagulation, endothelial dysfunction and oxidative stress in prediabetes - Biomarkers as a possible tool for early disease detection for rural screening

Clinical Biochemistry

Volumn 48, Issue 9, 2015, Pages 581-585

  Maschirow, L ^a   Khalaf, K ^b   Al Aubaidy, H A ^c   Jelinek, H F ^d,e  

^a UNIVERSITY OF POTSDAM   (Germany)

^b KHALIFA UNIVERSITY   (United Arab Emirates)

^c UNIVERSITY OF TASMANIA   (Australia)

^d MACQUARIE UNIVERSITY   (Australia)

^e CHARLES STURT UNIVERSITY   (Australia)

Author keywords

Coagulation; Endothelial dysfunction; Inflammation; Oxidative stress; Prediabetes

Indexed keywords

8 HYDROXYDEOXYGUANOSINE; 8 ISOPROSTANE; BIOLOGICAL MARKER; C REACTIVE PROTEIN; COMPLEMENT COMPONENT C5A; D DIMER; GLUTATHIONE; GLUTATHIONE DISULFIDE; HOMOCYSTEINE; INTERLEUKIN 6;

ADULT; ARTICLE; BLOOD CLOTTING; CONTROLLED STUDY; DIABETES MELLITUS; DIFFERENTIAL DIAGNOSIS; DISEASE COURSE; ENDOTHELIAL DYSFUNCTION; ERYTHROCYTE; FEMALE; FIBRINOLYSIS; GLUCOSE BLOOD LEVEL; HUMAN; IMPAIRED GLUCOSE TOLERANCE; INFLAMMATION; MAJOR CLINICAL STUDY; MALE; OXIDATIVE STRESS; PRIORITY JOURNAL; RURAL AREA; SCREENING; AGED; BLOOD; BLOOD ANALYSIS; EARLY DIAGNOSIS; HEALTH; MIDDLE AGED; PATHOPHYSIOLOGY; PREDIABETIC STATE; VASCULAR ENDOTHELIUM;

ADULT; AGED; BIOMARKERS; BLOOD CHEMICAL ANALYSIS; BLOOD COAGULATION; EARLY DIAGNOSIS; ENDOTHELIUM, VASCULAR; FEMALE; HUMANS; INFLAMMATION; MALE; MIDDLE AGED; OXIDATIVE STRESS; PREDIABETIC STATE; RURAL HEALTH;

EID: 84929957840     PISSN: 00099120     EISSN: 18732933     Source Type: Journal    
DOI: 10.1016/j.clinbiochem.2015.02.015     Document Type: Article

References (46)

1. IDF Diabetes Atlas http://www.Idf.Org/diabetesatlas/5e/the-global-burden.
2. The united states of diabetes: challenges and opportunities in the decade ahead. Working paper 5 2010, UnitedHealth Group.
3. Diagnosis and classification of diabetes mellitus. Diabetes Care 2004, 27:5-10.
4. Romeo J.H., Seftel A.D., Madhun Z.T., Aron D.C. Sexual function in men with diabetes type 2: association with glycemic control. J Urol 2000, 163:788-791.
5. Cade W.T. Diabetes-related microvascular and macrovascular diseases in the physical therapy setting. Phys Ther 2008, 88:1322-1335.
6. Rahman S., Rahman T., Ismail A.A.-S., Rashid A.R.A. Diabetes-associated macrovasculopathy: pathophysiology and pathogenesis. Diabetes Obes Metab 2007, 9:767-780.
7. Tabák A.G., Herder C., Rathmann W., Brunner E.J., Kivimäki M. Prediabetes: Ahigh-risk state for diabetes development. The Lancet. 2012, 379:2279-2290.
8. Barr E.L.M., Zimmet P.Z., Welborn T.A., Jolley D., Magliano D.J., Dunstan D.W., et al. Risk of cardiovascular and all-cause mortality in individuals with diabetes mellitus, impaired fasting glucose, and impaired glucose tolerance. Circulation 2007, 116:151-157.
9. Wilson J.M.G., G J. Principles and practice of screening for disease 1968, 26-27. WHO, Geneva.
10. Federation I.D. Global guideline for type 2 diabetes 2005, IDF Clinical Guidelines Task Force, Brussels.
11. Pradhan A., Manson J.E., Rifai N., Buring J.E., Ridker P.M. C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. JAMA 2001, 286:327-334.
12. Bloomgarden Z.T. Consequences of diabetes. Diabetes Care 2004, 27:1825-1831.
13. Patel V.B., Robbins M.A., Topol E.J. C-reactive protein: a 'golden marker' for inflammation and coronary artery disease. Cleve Clin J Med 2001, 68:521-524.
14. Giacco F., Brownlee M. Oxidative stress and diabetic complications. Circ Res 2010, 107:1058-1070.
15. Pop-Busui R. Cardiac autonomic neuropathy in diabetes. Diabetes Care 2010, 33:434-441.
16. Tan K.C.B., Chow W.-S., Ai V.H.G., Metz C., Bucala R., Lam K.S.L. Advanced glycation end products and endothelial dysfunction in type 2 diabetes. Diabetes Care 2002, 25:1055-1059.
17. Thorand B., Baumert J., Chambless L., Meisinger C., Kolb H., Döring A., et al. Elevated markers of endothelial dysfunction predict type 2 diabetes mellitus in middle-aged men and women from the general population. Arterioscler Thromb Vasc Biol 2006, 26:398-405.
18. Dincer Y., Akcay T., Alademir Z., Ilkova H. Effect of oxidative stress on glutathione pathway in red blood cells from patients with insulin-dependent diabetes mellitus. Metabolism 2002, 51:1360-1362.
19. Stocker R., Keaney J.F. Role of oxidative modifications in atherosclerosis. Physiol Rev 2004, 84:1381-1478.
20. Broedbaek K., Weimann A., Stovgaard E.S., Poulsen H.E. Urinary 8-oxo-7,8-dihydro-2'-deoxyguanosine as a biomarker in type 2 diabetes. Free Radic Biol Med 2011, 51:1473-1479.
21. Reassessing benefits and risks of statins. N Engl J Med 2012, 367:776.
22. Colhoun H.M., Betteridge D.J., Durrington P.N., Hitman G.A., Neil H.A., Livingstone S.J., et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the collaborative atorvastatin diabetes study (CARDS): multicentre randomised placebo-controlled trial. Lancet 2004, 364:685-696.
23. Franzoni F., Quiñones-Galvan A., Regoli F., Ferrannini E., Galetta F. A comparative study of the in vitro antioxidant activity of statins. Int J Cardiol 2003, 90:317-321.
24. Jackson Peter R., Wallis Erica J., Haq Ifti U., Ramsay L.E. Statins for primary prevention: at what coronary risk is safety assured?. Br J Clin Pharmacol 2001, 52:439-446.
25. Serdar Z., Aslan K., Dirican M., Sarandol E., Yesilbursa D., Serdar A. Lipid and protein oxidation and antioxidant status in patients with angiographically proven coronary artery disease. Clin Biochem 2006, 39:794-803.
26. Tracy R.P. Thrombin, inflammation, and cardiovascular disease: an epidemiologic perspective. Chest 2003, 124:49S-57S.
27. Al-Aubaidy H.A., Jelinek H.F. Oxidative DNA damage: antioxidant response in postprandial hyperglycaemia in type 2 diabetes mellitus. Br J Diabetes Vasc Dis 2011, 11:87-91.
28. Nwose E.U., Jelinek H.F., Richards R.S., Kerr P.G. Changes in the erythrocyte glutathione concentration in the course of diabetes mellitus. Redox Rep 2007, 12:162.
29. Al-Aubaidy H.A., Jelinek H.F. 8-hydroxy-2-deoxy-guanosine identifies oxidative DNA damage in a rural prediabetes cohort. Redox Rep 2010, 15:155-160.
30. Yang H., Jin X., Kei Lam C.W., Yan S.K. Oxidative stress and diabetes mellitus. Clin Chem Lab Med 2011, 49:1773-1782.
31. Rosen P., Nawroth P.P., King G., Moller W., Tritschler H.J., Packer L. The role of oxidative stress in the onset and progression of diabetes and its complications: a summary of a congress series sponsored by UNESCO-MCBN, the American Diabetes Association and the German Diabetes Society. Diabetes Metab Res Rev 2001, 17:189-212.
32. Penckofer S., Schwertz D., Florczak K. Oxidative stress and cardiovascular disease in type 2 diabetes: the role of antioxidants and pro-oxidants. J Cardiovasc Nurs 2002, 16:68-85.
33. Beckman J.A. Endothelial dysfunction. Diabetes and cardiovascular disease integrating science and clinical medicine 2004, 239-250. Lippincott Williams & Wilkins, Philadelphia. S.P.M.D.M. Stern (Ed.).
34. Devaraj S., Vega-Lopez S., Jialal I. Antioxidants, oxidative stress, and inflammation in diabetes. Diabetes and cardiovascular disease integrating science and clinical medicine 2004, 19-35. Lippincott Williams & Wilkins, Philadelphia. S.P.M.D.M. Stern (Ed.).
35. Baker M.A., Cerniglia G.J., Zaman A. Microtiter plate assay for the measurement of glutathione and glutathione disulfide in large numbers of biological samples. Anal Biochem 1990, 190:360-365.
36. Griffith O.W. Determination of glutathione and glutathione disulfide using glutathione reductase and 2-vinylpyridine. Anal Biochem 1980, 106:207-212.
37. Ishihara O., Hayashi M., Osawa H., Kobayashi K., Takeda S., Vessby B., et al. Isoprostanes, prostaglandins and tocopherols in pre-eclampsia, normal pregnancy and non-pregnancy. Free Radic Res 2004, 38:913-918.
38. Al-Aubaidy H.A., Jelinek H.F. Oxidative DNA damage and obesity in type 2 diabetes mellitus. Eur J Endocrinol 2011, 164:899-904.
39. Kobayashi S., Susa T., Tanaka T., Wada Y., Okuda S., Doi M., et al. Urinary 8-hydroxy-2'-deoxyguanosine reflects symptomatic status and severity of systolic dysfunction in patients with chronic heart failure. Eur J Heart Fail 2011, 13:29-36.
40. Dumaswala U.J., Zhuo L., Mahajan S., Nair P.N.M., Shertzer H.G., Dibello P., et al. Glutathione protects chemokine-scavenging and antioxidative defense functions in human RBCs. Am J Physiol Cell Physiol 2001, 280:C867-C873.
41. Schnabel R., Lackner K.J., Rupprecht H.J., Espinola-Klein C., Torzewski M., Lubos E., et al. Glutathione peroxidase-1 and homocysteine for cardiovascular risk prediction: results from the AtheroGene study. J Am Coll Cardiol 2005, 45:1631-1637.
42. Faeh D., Chiolero A., Paccaud F. Homocysteine as a risk factor for cardiovascular disease: should we (still) worry about? 2006.
43. Yeh E.T.H., Willerson J.T. Coming of age of C-reactive protein. Circulation 2003, 107:370-371.
44. Manthey H.D., Woodruff T.M., Taylor S.M., Monk P.N. Complement component 5a (C5a). Int J Biochem Cell Biol 2009, 41:2114-2117.
45. Nwose E.U., Richards R.S., Jelinek H.F., Kerr P.G. D-dimer identifies stages in the progression of diabetes mellitus from family history of diabetes to cardiovascular complications. Pathology 2007, 39:252-257.
46. Nwose E.U., Jelinek H.F., Richards R.S., Tinley P., Kerr P.G. Atherothrombosis and oxidative stress: the connection and correlation in diabetes. Redox Rep 2009, 14:55-60.